ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
82,699.09
5.38%
S&P 500
5,572.07
-0.76%
Dow Jones
41,433.48
-1.14%
US Dollar vs Yen
147.8245
0.51%
Brent Oil
69.635
0.86%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Benitec Biopharma Limited (BNTC)

  7. Benitec Biopharma Limited (BNTC) ニュース

BNTC

Benitec Biopharma (BNTC)

Benitec Biopharma Limited
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:BNTC
日付受信時刻ニュースソース見出しコード企業名
2025/02/1422 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2025/02/1421 : 51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BNTCBenitec Biopharma Limited
2025/01/0407 : 39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BNTCBenitec Biopharma Limited
2024/12/3120 : 34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:BNTCBenitec Biopharma Limited
2024/12/1406 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/12/1208 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BNTCBenitec Biopharma Limited
2024/12/1207 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BNTCBenitec Biopharma Limited
2024/12/1207 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BNTCBenitec Biopharma Limited
2024/12/1107 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/12/0707 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/11/1506 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/11/1506 : 35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BNTCBenitec Biopharma Limited
2024/11/1506 : 32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BNTCBenitec Biopharma Limited
2024/11/1506 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/11/1314 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BNTCBenitec Biopharma Limited
2024/11/0206 : 04Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BNTCBenitec Biopharma Limited
2024/10/2322 : 23Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BNTCBenitec Biopharma Limited
2024/10/2306 : 24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BNTCBenitec Biopharma Limited
2024/10/1521 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/10/1519 : 08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BNTCBenitec Biopharma Limited
2024/10/1206 : 13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BNTCBenitec Biopharma Limited
2024/10/1205 : 53Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BNTCBenitec Biopharma Limited
2024/10/1205 : 52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/10/0905 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/10/0205 : 46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BNTCBenitec Biopharma Limited
2024/09/2705 : 43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
2024/09/2705 : 30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BNTCBenitec Biopharma Limited
2024/07/3005 : 28Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BNTCBenitec Biopharma Limited
2024/07/2005 : 59Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BNTCBenitec Biopharma Limited
2024/07/1606 : 18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BNTCBenitec Biopharma Limited
 Showing the most relevant articles for your search:NASDAQ:BNTC

最近閲覧した銘柄

COIN
DOGEUSD
Dogecoin
NYSE
AXP
American Express
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
SILVER
SILVER
PM
XAUUSD
Gold vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
NYSE
KO
Coca Cola
NYSE
MRK
Merck
COIN
AVAXUSD
Avalanche
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す